SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is surging after a preliminary business update revealed record order growth and significantly higher-than-expected gross margins, signaling robust AI infrastructure demand that has caught short sellers off guard. The community is actively debating the potential for an imminent short squeeze and whether these improved fundamentals will lead to a sustained re-rating of the stock price.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is facing a sell-off as investors react to reports of delays in its flagship Gemini 3.5 Pro model, fueling concerns about Google's ability to maintain pace with competitors like OpenAI and Anthropic. The community remains divided, with some viewing the drop as a temporary overreaction and an accumulation opportunity, while others worry the setback highlights broader execution challenges in the competitive AI landscape.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR is currently trending due to community excitement surrounding its role in the AI-blockchain narrative and recent technical developments, with many investors actively debating whether to accumulate during the current period of market volatility. Discussion boards are heavily focused on its long-term potential as decentralized infrastructure, alongside speculation on how institutional adoption and broader sector rotations will influence its future price action.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is facing heightened investor scrutiny as reports of development delays for its flagship Gemini AI models spark concerns over the company's competitive positioning against rivals like Anthropic and OpenAI. While the market remains divided on whether these setbacks represent a structural weakness or a strategic adjustment, analysts are closely monitoring upcoming capital expenditure guidance to determine if Google's massive investments in AI infrastructure will translate into sustainable long-term profitability.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is seeing heightened trading volume and social activity as investors debate the potential for a new growth phase driven by its role in Japan's blockchain ecosystem and evolving IoT data use cases. While some community members are actively accumulating based on long-term project belief, others express deep skepticism regarding the asset's utility and historical price performance, leading to intense friction between bullish long-term holders and bearish traders.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the following segments: Materials and Magnetics. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is under pressure as China adds the company to its export control list, sparking investor uncertainty despite the firm's strategic push for supply chain independence. The community is actively debating the stock's long-term potential as a critical defense asset versus its recent technical volatility and the impact of broader sector-wide selling.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is capturing significant investor attention following the executive order to fast-track psychedelic drug research, though the sudden departure of its interim CEO has fueled volatility and intense community debate over management stability. Despite retail excitement surrounding potential priority vouchers and clinical milestones, active discussions frequently focus on the tension between the company's Breakthrough Therapy designation, its cash runway, and ongoing concerns regarding dilution and leadership changes.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell Technologies is trending as investors rally around the company's role as a leading enterprise AI server provider, with many in the community citing strong order backlogs and the stock's relative strength compared to other hardware peers. While some participants are actively discussing the stock's technical breakout potential toward new highs, others are debating whether its current valuation is sustainable given broader market volatility and concerns over legacy business exposure.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power is gaining renewed attention as investors weigh the stock's long-term potential in the nuclear energy sector against ongoing frustration over a lack of major contract announcements and consistent share dilution. The community remains deeply divided, with some traders optimistic that mounting energy demand from AI data centers will eventually act as a major catalyst, while others are wary of the stock's persistent downtrend and management's perceived lack of urgency.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is trending as investors weigh geopolitical risks in the Middle East against central bank gold accumulation and shifts in global monetary policy. The community is actively debating the metal's role as a hedge against inflation and sovereign debt, with many focusing on decoupling trends from tech stocks and potential decoupling from paper-based price discovery systems.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Monday Sector Leaders: Biotechnology, Oil & Gas Refining & Marketing Stocks

In trading on Monday, biotechnology shares were relative leaders, up on the day by about 2.1%. Leading the group were shares of Insight Molecular Diagnostics, up about 22.8% and shares of Replimune...

Insider Buying: Oncocyte (NASDAQ:IMDX) Major Shareholder Purchases 250,923 Shares of Stock

Oncocyte Corp (NASDAQ:IMDX - Get Free Report) major shareholder Broadwood Partners, L.P. bought 250,923 shares of the firm's stock in a transaction dated Monday, April 27th. The stock was acquired at...

Broadwood Partners, L.P. Buys 250,923 Shares of Oncocyte (NASDAQ:IMDX) Stock

Oncocyte Corp (NASDAQ:IMDX - Get Free Report) major shareholder Broadwood Partners, L.P. acquired 250,923 shares of the firm's stock in a transaction that occurred on Monday, April 27th. The stock...

Oncocyte (NASDAQ:IMDX) Major Shareholder Broadwood Partners, L.P. Acquires 280,381 Shares

Oncocyte Corp (NASDAQ:IMDX - Get Free Report) major shareholder Broadwood Partners, L.P. acquired 280,381 shares of the company's stock in a transaction dated Thursday, April 23rd. The shares were...

Oncocyte (NASDAQ:IMDX) Major Shareholder Broadwood Partners, L.P. Purchases 38,880 Shares

Oncocyte Corp (NASDAQ:IMDX - Get Free Report) major shareholder Broadwood Partners, L.P. bought 38,880 shares of the stock in a transaction dated Friday, April 24th. The stock was purchased at an...

Broadwood Partners, L.P. Purchases 40,114 Shares of Oncocyte (NASDAQ:IMDX) Stock

Oncocyte Corp (NASDAQ:IMDX - Get Free Report) major shareholder Broadwood Partners, L.P. acquired 40,114 shares of Oncocyte stock in a transaction that occurred on Friday, April 17th. The shares were...

Oncocyte (NASDAQ:IMDX) Major Shareholder Purchases $352,096.65 in Stock

Oncocyte Corp (NASDAQ:IMDX - Get Free Report) major shareholder Broadwood Partners, L.P. purchased 102,057 shares of Oncocyte stock in a transaction on Thursday, April 16th. The stock was acquired at...

Oncocyte (NASDAQ:IMDX) Major Shareholder Acquires $157,877.20 in Stock

Oncocyte Corp (NASDAQ:IMDX - Get Free Report) major shareholder Broadwood Partners, L.P. purchased 40,690 shares of Oncocyte stock in a transaction dated Monday, April 20th. The stock was bought at...

Oncocyte (NASDAQ:IMDX) Major Shareholder Acquires $143,206.98 in Stock

Oncocyte Corp (NASDAQ:IMDX - Get Free Report) major shareholder Broadwood Partners, L.P. acquired 40,114 shares of the stock in a transaction that occurred on Friday, April 17th. The shares were...

Tuesday Sector Leaders: Biotechnology, Medical Instruments & Supplies

In trading on Tuesday, biotechnology shares were relative leaders, up on the day by about 3.4%. Leading the group were shares of Travere Therapeutics, up about 34.1% and shares of Insight Molecular Diagnostics up about 33% on the day.

Also showing relative strength are medical...

Insight Molecular Diagnostics, Inc. is a diagnostics technology company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The company was founded in September 2009 and is headquartered in Nashville, TN.

Insight Molecular Diagnostics Inc.

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.24	--	--	N/A
Q1 '26	-$0.26	-$0.12	54.12%	BEAT
Q4 '25	-$0.24	-$0.72	-203.16%	MISSED
Q3 '25	-$0.21	-$0.20	4.74%	BEAT
Q2 '25	-$0.23	-$0.30	-30.43%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

IMDXInsight Molecular Diagnostics Inc.

Upcoming Earnings: Q2 '26

Historical Earnings

Latest IMDX News